Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs

Shuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, Connie Lesnick, Shuhei Yamada, Naoki Ueda, Takashi Suzuki, Shuya Yamashita, Yoon Hee Kim, Yoshinori Fujimura, Daisuke Miura, Neil E. Kay, Tait D. Shanafelt, Hirofumi Tachibana

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma.

Original languageEnglish
Pages (from-to)2303-2312
Number of pages10
JournalMolecular Cancer Therapeutics
Volume14
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Sphingomyelin Phosphodiesterase
Laminin Receptors
Multiple Myeloma
Apoptosis
Acids
Ceramides
Receptor Protein-Tyrosine Kinases
Neoplasms
Cell Death
Death-Associated Protein Kinases
Polyphenols
Tea
Phosphorylation
Lipids
sphingosine kinase
epigallocatechin gallate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs. / Tsukamoto, Shuntaro; Huang, Yuhui; Kumazoe, Motofumi; Lesnick, Connie; Yamada, Shuhei; Ueda, Naoki; Suzuki, Takashi; Yamashita, Shuya; Kim, Yoon Hee; Fujimura, Yoshinori; Miura, Daisuke; Kay, Neil E.; Shanafelt, Tait D.; Tachibana, Hirofumi.

In: Molecular Cancer Therapeutics, Vol. 14, No. 10, 01.10.2015, p. 2303-2312.

Research output: Contribution to journalArticle

Tsukamoto, S, Huang, Y, Kumazoe, M, Lesnick, C, Yamada, S, Ueda, N, Suzuki, T, Yamashita, S, Kim, YH, Fujimura, Y, Miura, D, Kay, NE, Shanafelt, TD & Tachibana, H 2015, 'Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs', Molecular Cancer Therapeutics, vol. 14, no. 10, pp. 2303-2312. https://doi.org/10.1158/1535-7163.MCT-15-0185
Tsukamoto, Shuntaro ; Huang, Yuhui ; Kumazoe, Motofumi ; Lesnick, Connie ; Yamada, Shuhei ; Ueda, Naoki ; Suzuki, Takashi ; Yamashita, Shuya ; Kim, Yoon Hee ; Fujimura, Yoshinori ; Miura, Daisuke ; Kay, Neil E. ; Shanafelt, Tait D. ; Tachibana, Hirofumi. / Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 10. pp. 2303-2312.
@article{fd11db7fa21a4a7c90ba489bc5fadb41,
title = "Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs",
abstract = "Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma.",
author = "Shuntaro Tsukamoto and Yuhui Huang and Motofumi Kumazoe and Connie Lesnick and Shuhei Yamada and Naoki Ueda and Takashi Suzuki and Shuya Yamashita and Kim, {Yoon Hee} and Yoshinori Fujimura and Daisuke Miura and Kay, {Neil E.} and Shanafelt, {Tait D.} and Hirofumi Tachibana",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0185",
language = "English",
volume = "14",
pages = "2303--2312",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs

AU - Tsukamoto, Shuntaro

AU - Huang, Yuhui

AU - Kumazoe, Motofumi

AU - Lesnick, Connie

AU - Yamada, Shuhei

AU - Ueda, Naoki

AU - Suzuki, Takashi

AU - Yamashita, Shuya

AU - Kim, Yoon Hee

AU - Fujimura, Yoshinori

AU - Miura, Daisuke

AU - Kay, Neil E.

AU - Shanafelt, Tait D.

AU - Tachibana, Hirofumi

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma.

AB - Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84946772116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946772116&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0185

DO - 10.1158/1535-7163.MCT-15-0185

M3 - Article

C2 - 26264277

AN - SCOPUS:84946772116

VL - 14

SP - 2303

EP - 2312

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -